跳至主要内容
临床试验/JPRN-UMIN000013343
JPRN-UMIN000013343已完成4 期

Assessment of suitable Antihypertensive therapies: Combination with high dose amlodipine/Irbesartan vs. triple combination with amlodipine/Irbesartan/Indapamide - ASAHI-AI study

Asahikawa Medical University0 个研究点目标入组 94 人开始时间: 2014年3月6日最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
入组人数
94

研究概览

简要总结

High-dose CCBs combined with ARBs and a triple combination with diuretics combined with standard-dose CCB/ARBs produced a similar efficacy in reducing the BP. Both combination therapies can be used safely and effectively in hypertensive patients uncontrolled by standard doses of ARBs and CCBs.

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 85years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1) Patients with secondary hypertension 2) Patients with a history of severe renal disease: serum creatinine>2.0 mg/dl 3) Patients with critical liver damage (AST or ALT>100 IU/l) 4) Patients with a history of adverse effects to ARBs 5) Bilateral renal artery stenosis 6) Patients with hyperkalemia >=5.5 mEq/L 7) Patients with pregnancy or breast-feeding 8) Patients with a poor prognosis such as a malignant tumor 9) Patients who are considered not to be eligible for the study by the investigator due to medical reasons

研究者

相似试验